H.C. Wainwright analyst Robert Burns lowered the firm’s price target on BioNTech to $107 from $133 and keeps a Buy rating on the shares. The firm took into account lower long-term Comirnaty revenues. It also views BNT323 as a potential driver of future upside to forecasts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNTX:
- BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
- SHAREHOLDER ALERT: Potential Recovery for BioNTech SE (BNTX) Investors
- Outlook Letdown Prompts BioNTech (NASDAQ:BNTX) Slide
- BioNTech provides strategic priorities and company update
- BioNTech sees FY24 revenue EUR3.0B, consensus $4.17B
